One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases. Hanmi Pharmaceutical's Global Business ...

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen. The ESG in Life Sciences Summit West is ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition.

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.

EU Approval for the Expanded Use of AZN’s Key Cancer Drugs AstraZeneca announced that the EC has approved the expanded use of Imfinzi in combination with chemotherapy for treating adults with ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

When AstraZeneca gobbled up Alexion Pharmaceuticals in one of the biggest-ever takeovers of a Boston company, there was some hope it might mean more jobs here instead of the cuts that often follow ...